| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.2 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.2 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.2 |